Kornimate/medical-research-clean huggingface dataset:
the effect of general anesthesia on the risk for arrhythmia

Conditions: Arrhythmia

Summary: polymorphic ventricular tachycardia, known as torsades de pointes (tdp), is a specific form of ventricular arrhythmia with a characteristic twist of the qrs complex around the isoelectric baseline. tdp can degenerate into ventricular defibrillation followed by sudden cardiac death. a predictor for the development of tdp is the length of the qt interval measured on an ekg recording. the qt interval is known to be prolonged by many medications used in a perioperative setting as well as by other conditions such as hypothermia and electrolyte imbalance. general anesthesia exposes most of the investigators patients to a combination of several of those medications and conditions and therefore might increase the risk for the development of qt prolongation. moreover, patient related risk factors are well known and aggravate the individual risk for potential life threatening tdp events when exposed to qt prolonging medications perioperatively. previous research suggests that more than 20% of the patients might develop qt prolongations perioperatively and are consequently on an increased risk for tdp; yet, no study has systematically investigated the magnitude of the problem and associated risk factors. the proposed pilot study is designed as a prospective observational cohort study to investigate the qt interval before, during and after general anesthesia. it aims to determine the incidence of perioperative qt prolongations. a customary long term ekg recording device will be connected to a random sample of patients undergoing general anesthesia. using these continuous ekg tracings, the lengths of the qt interval will be analyzed during the perioperative period.


Eligibility criteria:
inclusion criteria: * male and female asa i - iii patients * age 18 years and older * scheduled for general anesthesia with a duration of at least 1 hour exclusion criteria: * cardiac or thoracic surgery * planed postoperative icu admission * non-english speaking * not in sinus rhythm * left and right bundle branch block * implanted pacemaker * mentally impaired

Keywords: general anesthesia electrocardiography long qt syndrome, acquired
third stage of labor a swedish randomized controlled trial

Conditions: Childbirth

Summary: the purpose with this study was to compare blood loss and women's experience of afterpains during the third stage when handled with active or expectant management of the third stage of labour. hypothesis 1. to detect a 5% difference (15% vs 10%) in blood loss \>1000 ml between the two groups with 80% power (α=0.05), at least 726 subjects were required in each group. hypothesis 2. afterpains are more pronounced in active compared to expectant management during the third stage of labour

management of the third stage of labour has been focus for investigation during decades and active management of the third stage of labour (amtsl)has been recommended in all women giving birth vaginally at hospitals. in sweden the recommendation has been to give an injection of oxytocin immediately after birth of the neonate but not the entire amtsl procedure. women in labour were asked to participate voluntarily when entering the hospital and after acceptance they were randomised to either active or expectant management of the third stage of labour(emtsl). amtsl included: * early cord clamping * 10 ui oxytocin i.v * controlled cord traction * uterine massage after placenta expulsion emtsl included: * early cord clamping * 2 ml saline solution i.v * wait for signs of placenta detachment * encourage the women to push out placenta by her own effort * uterine massage after placenta expulsion all blood was measured by weighing bed pads and sanitary towels up to two hours postpartum assessment of afterpains was performed by a visual analogue scale (vas) and the pain-o-meter (pom-wds) two hours after the delivery of placenta, and the day after childbirth.

Eligibility criteria:
inclusion criteria: * healthy women with normal pregnancies * gestational age of 34+0 - 43+0 weeks * singleton, cephalic presentation * expected vaginal birth exclusion criteria: * non swedish-speaking * previous pph \>1000 ml * elective caesarean section * pre-eclampsia * grand multiparity (≥5) * intrauterine fetal death

Keywords: third stage of labor,oxytocics, postpartum hemorrhage,
radiotherapy combined with gdp with or without chidamide in stage i/ii extranodal nasal nk/t-cell lymphoma

Conditions: Lymphoma

Summary: currently, combined chemotherapy (ct) and radiation (rt) is recognized as the standard treatment for high-risk early-stage nktcl. however, treatment failure occured in nearly 30% of patients receiving crt and systemic failure are the most common failure form. chidamide is a hadc inhibitor, which presents satisfactory efficacy in nktcl especially in terms of improving durable remission time. in our previous study, imrt followed by gdp was demonstrated effective in early-stage nktcl. therefore, we designed a prospective phase ii clinical trial of imrt followed by gdp with or without chidamide in patients with high-risk early-stage nktcl.


Eligibility criteria:
inclusion criteria: 1. diagnosis of nktcl with typical morphology and immunophenotype, according to the 2008 world health organization classification of lymphomas; 2. no prior radiotherapy or chemotherapy; 3. age ≥ 18 years; 4. ecog performance status 0-2; 5. ann arbor stages i and ii; 6. tumors primarily occurring in the upper aerodigestive tract; 7. at least one unfavorable prognostic factor (age \> 60 years, b symptoms, elevated ldh, ecog score 2, regional node involvement, and pti); 8. at least one measurable lesion; 9. adequate hematological, hepatic, and renal functions; e.g., absolute neutrophil count ≥ 1.5 × 109/l, platelet count ≥ 80 × 109/l, total bilirubin ≤ 1.5 × upper limit of normal, alanine transaminase and aspartate transaminase ≤ 2 × upper limit of normal, and creatinine ≤ 1.5 mg/dl; 10. life expectancy of more than 3 months. exclusion criteria: 1. patients with advanced stage disease; 2. pregnancy or lactation; 3. any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol.
treatment safety and efficacy of pro-ocular™ 1% for chronic ocular graft following allogeneic hsct.

Conditions: Chronic Ocular Graft-versus-host Disease

Summary: to evaluate the safety and efficacy of pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular gvhd.

ocular graft versus host disease presents a most severe form of ocular surface disease that compromises quality of life of afflicted allogeneic hematopoietic transplantation patients. a controlled study is necessary to verify findings obtained to date in isolated patients. currently available ophthalmic solutions and suspensions, drugs and devices largely have not been effective in alleviating the suffering of chronic ocular gvhd patients. thus, this is an unmet need that pro-ocular™ topical gel can fulfill. potential benefits: decrease or cessation of adverse ocular symptoms and signs of chronic ocular gvhd, reduction or elimination of the need for other topical ocular therapeutic treatments for chronic ocular gvhd, and restoration of quality of life.

Eligibility criteria:
inclusion criteria: 1. male or female of any race, at least 18 years of age at visit 1 screening. 2. has the diagnosis of chronic ocular gvhd. 3. has an nih consensus eye score of at least 2. 4. on the glia ocular surface disease symptoms questionnaire at screening, has ocular discomfort at a severity score of moderate or more, and at least one other symptom at a severity of moderate or more. 5. one or more signs from the list of chronic ocular gvhd signs below 6. has provided verbal and written informed consent. 7. be able and willing to follow oral and written instructions, including participation in all study assessments and visits. exclusion criteria: 1. wearing scleral or contact lenses within the last month, or those who plan to start wearing scleral or contact lenses during the study. 2. anticipate major changes in systemic gvhd management during study period. 3. comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such as but not limited to retinal detachment, recent ocular surgery, bell's palsy, active trigeminal neuritis or trigeminal neuralgia. 4. anticipate change of vision correction or anticipate any ocular procedures during study period. 5. a woman who is pregnant, nursing an infant, or planning a pregnancy. 6. a woman of childbearing potential who has a positive urine pregnancy test at visit 1, or who does not use an adequate method of birth control throughout the study period. 7. has a known adverse reaction and/or sensitivity to the study drug or its components. 8. unwilling to cease the use of sunscreen on the forehead or eye area. 9. intraocular pressure \>22 mm hg at screening visit with or without ongoing glaucoma treatment. 10. currently enrolled in an investigational drug or device study for chronic ocular gvhd.
"fu-ifm2009" database post ifm/dfci 2009 study

Conditions: Multiple Myeloma

Summary: extension of patient follow-up of the ifm/dfci 2009 study over a period of 4 years (that is, from 01 december 2016 to 30 november 2020) during which patients will be followed up in the normal course of care and according to the usual care of the centers, with collection of the needed data about twice a year by the investigators


Eligibility criteria:
inclusion criteria: * patient randomized in the ifm/dfci 2009 study. * patient still alive must give their non-opposition to the post ifm/dfci 2009 study data collection until 30 november 2020 * patient non-opposition.
subjective evaluation of a sound processing method for hearing aids on auditory distance perception

Conditions: Hearing Disorders; Hearing Loss, Sensorineural

Summary: within the course of this study, a signal processing feature has been developed at ecole polytechnique fédérale de lausanne (epfl), in collaboration with sonova ag, in order to enhance the listening experience with remote microphone systems. in particular, the developed feature is supposed to improve the so-called audio-visual fusion, i.e. the fact to perceive the sound as coming from the physical location of the source. one of the main goals of the present study is to evaluate the extent to which this feature reaches that objective.


Eligibility criteria:
subjects fulfilling all of the following inclusion criteria are eligible for the study: * willing and able to give written informed consent as documented by signature, * french-native adult speakers, * (preferably) younger than 60 y.o. for all normal-hearing participants: - hearing thresholds lower or equal to 20 db on both ears, as ensured by a pure-tone audiometry (125 hz to 8 khz) conducted at the beginning of the session. for all hearing-impaired patients: * patients of mr. philippe estoppey, private audiologist settled in lausanne, * user of bilateral bte phonak hearing aids, commercialized after july 2012, with fittings that did not change over the last three months, * presenting a severe-to-profound sensorineural hearing loss, * presenting a symmetrical hearing loss (no bilateral hearing threshold that differ by more than 20 db at any audiometric frequency (125 hz - 4 khz)). for hi patients experienced with remote microphone systems: - past or present users of fm and/or roger devices for more than six months. for other hi patients: - no past or present experience with fm and/or roger devices for more than one month. the presence of any one of the following exclusion criteria will lead to exclusion of the participant: * collaborator of the laboratory (lts2) or student attending the courses of audio and acoustics given by the laboratory staff (ee-348 electroacoustics, ee-548 audio engineering), * history of chronic or terminal illness, psychiatric disturbance, senile dementia, or cognitive impairment, * history of strong tinnitus and/or hyperacusis, * strong visual impairment after correction with glasses or not, * history of epilepsy or other reactions associated with the proximity to a screen, * motor disability that would disturb their presence at epfl.

Keywords: hearing aids remote microphone systems roger technology sound externalization auditory distance estimation
feasibility of prophylactic haldol to prevent delirium in cancer patients

Conditions: Stem Cell Transplant Complications; Delirium

Summary: this research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (hsct). the study will address the following research aims: 1) to demonstrate the feasibility of enrolling hsct patients in a prophylactic medication trial, 2) to determine the tolerability of oral haldol in hsct patients and 2) to compare rates of delirium in hsct patients who receive prophylactic haldol with an untreated historical control group.

this is an open label, safety \& feasibility, clinical drug trial. we will use historical controls from previous research with bone marrow transplant patients and delirium incidence at university of iowa hospitals and clinics (uihc) to evaluate the efficacy of prophylactic haldol in the prevention of delirium. this study will recruit adult cancer patients undergoing hematopoietic stem cell transplant (hsct) at uihc.

Eligibility criteria:
inclusion criteria: * the participant must undergo an autologous or allogeneic bone marrow or stem cell transplant * the participant is 18 years of age or older * the participant provides written consent exclusion criteria: * the participant has a qtc of \>450 msec at the time of enrollment * the participant used any antipsychotic medications within the last 30 days * the participant has any significant allergies or past intolerance to haloperidol * the participant has a history of major neurological, metabolic, psychiatric, or cardiovascular disease, cerebrovascular event, or substance abuse * the participant has a history of mental retardation or learning disability that, at the discretion of the investigator, could affect their ability to complete study assessments.
efficacy of nasal irrigation with respimer® netiflow® vs saline among patients with cystic fibrosis and chronic rhinosinusitis

Conditions: Chronic Rhinosinusitis; Cystic Fibrosis

Summary: prospective, randomized, cross-over, multicenter, trial comparing the efficacy and tolerability of nasal irrigation with respimer® mineral salts solution versus saline solution both administered with respimer® netiflow® medical device among patients aged ≥ 11 years and older with cystic fibrosis and suffering from chronic rhinosinusitis.


Eligibility criteria:
inclusion criteria: * • patient with cystic fibrosis with or without lung transplant; * patients with allergic chronic rhino sinusitis or no allergic diagnosed by the clinical investigator on the basis of the following signs in variable combination: nasal congestion, headache, sneezing, itchy nose and eyes, runny nose, nosebleeds and nasal crusts, redness and eye discharge present more than 3 months per year. * patient treated on an outpatient basis; * patient agreeing not to take sea baths for the duration of the study; * patient agreeing to respect the procedures for conducting the study, in particular the washout period and follow-up visits; * patient capable of understanding and self-completing the questionnaires; * for juvenile patients, the holder (s) of parental authority have accepted the participation of the young person (by signing the informed consent after having taken note of the information note) * member or beneficiary of a social security program exclusion criteria: * patients with significant obstruction of the nasal passages due to: * a mucocele, * polyposis causing nasal obstruction\> 90% or * severe malformation of the septum causing a nasal obstruction\> 90% in whom surgical treatment is recommended; * patients with signs of severity that may require hospitalization, such as: severe impairment of general health, dyspnoea with cyanosis, high fever (\> 40 ° c). * patients requiring corticosteroid therapy during the study, with the exception of patients who received pulmonary transplant and were treated with oral corticosteroids at no more than 0.2 mg / kg / day. * patients with known systemic immunodeficiency status with the exception of patients receiving pulmonary transplantation and immunosuppressed. * patient pregnant (urine test) or without effective contraception (birth control pill, contraceptive patch, contraceptive implant, vaginal ring, intrauterine device or intrauterine device, male condom). * nursing patient. * patient with a contraindication to nasal irrigations as defined in the product leaflet.

Keywords: saline solution minerals cystic fibrosis chronic rhinosinusitis nasal irrigation
epidemiological characteristics and prevention methods of blisters in ultra-trail runners

Conditions: Sport Injury; Blister of Foot

Summary: primary objective : to evaluate the methods of prevention of the appearance of blisters set up by the runners before and during an ultra-trail secondary objectives : to evaluate : * the main locations of blisters. * the severity of blisters * the effectiveness of prevention methods to evaluate the incidence of blisters in an ultra-trail context.

main judgement criteria : prevention methods used before an ultra-trail via a self-questionnaire secondary judging criteria : location of blisters, via a self-questionnaire presence or not of blisters at the end of the ultra-trail or at the time of abandonment study scheme : post-race questioning

Eligibility criteria:
inclusion criteria: * ultra-trail participants with validated registration exclusion criteria: * presence of blisters or other skin lesions on the feet before the race
mass scan as a predictor of morbidity and mortality in patients with liver disease

Conditions: Liver Diseases

Summary: the purpose of the study is to study the muscle assessment score (mass, utilizing mri, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

prospective study of patients seen at the univ. of chicago medical center hospital and ambulatory clinics. the assessment of the mass score will require an additional 8-10 minutes in the mri for each patient already undergoing mri exam. four groups of pts. who are already scheduled for mri for routine clinical purposes will be evaluated. 1. pts. hospitalized with acute hepatic decompensation for whom mri is otherwise indicated for clinical evaluation. 2. pts. with hepatobiliary neoplasia 3. pts.undergoing transjugular portosystemic shunt (tips) placement 4. pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Eligibility criteria:
inclusion criteria: * patients who are already scheduled for an mri for routine clinical purposes will be evaluated exclusion criteria: * \<18 yrs. of age
an study of transcranial direct current stimulation in adults with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this pilot study is to determine whether transcranial direct current stimulation safely and effectively improves symptoms of adhd.


Eligibility criteria:
inclusion criteria: * male and female adults 18-65 years of age. * a diagnosis of childhood onset adhd, meeting the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) \[american psychiatric association, 2013\] criteria, including at least 5 moderate inattentive or impulsive-hyperactive symptoms, and onset of several symptoms of inattentive or of impulsive/hyperactive traits by the age of 12. * english-speaking. exclusion criteria: - current or past history of mental retardation, severe sensory impairment such as deafness or blindness, hypomania, mania, psychosis, suicidal or homicidal behavior. current moderate to severe symptoms of a mental health condition other than adhd, assessed using a clinical evaluation and the adult self report scale that, in the judgment of the investigator, may jeopardize subject safety or interfere with their ability to participate in the study. specifically, this will include current clinical diagnosis of moderate to severe major depression, or a score on the depressive problem subscale of the asrs that falls in the clinically significant range. * substance use disorder within the past 6 months. * any significant medical condition, that, in the judgment of the investigator, may jeopardize subject safety. * pregnant females. * inability or unwillingness to participate in study procedures. * contraindication to tdcs: history of epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, vp shunt, or pacemakers. * skin conditions that may make the application of, treatment with, and removal of the tdcs hardware painful as per the discretion of the clinician. * current use of a medication considered to be therapeutic for adhd. if a subject is taking a medication that is considered by study investigators to potentially treat adhd (eg. a stimulant, atomoxetine, buproprion, modafanil, serotonin-norepinephrine reuptake inhibitor, guanfacine or clonidine) they must stop use of this medication for at least 5 half lives of the drug under physician guidance prior to study participation. subjects will not enter the study if it would require stopping a medication that is optimally and comfortably managing a clinical concern.